{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:24:42Z","timestamp":1789608282402,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vancomycin is the most commonly administered antibiotic in hospitalized patients, but optimal exposure targets remain controversial. To clarify the therapeutic exposure range, this study evaluated the association between vancomycin exposure and outcomes in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective, multicenter (n = 14), observational study of 265 hospitalized adults with MRSA bacteremia treated with vancomycin. The primary outcome was treatment failure (TF), defined as 30-day mortality or persistent bacteremia \u22657 days. Secondary outcomes included acute kidney injury (AKI). The study was powered to compare TF between patients who achieved or did not achieve day 2 area under the curve to minimum inhibitory concentration (AUC\/MIC) thresholds previously found to be associated with lower incidences of TF. The thresholds, analyzed separately as co-primary endpoints, were AUC\/MIC by broth microdilution \u2265650 and AUC\/MIC by Etest \u2265320.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment failure and AKI occurred in 18% and 26% of patients, respectively. Achievement of the prespecified day 2 AUC\/MIC thresholds was not associated with less TF. Alternative day 2 AUC\/MIC thresholds associated with lower TF risks were not identified. A relationship between the day 2 AUC and AKI was observed. Patients with day 2 AUC \u2264515 experienced the best global outcomes (no TF and no AKI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher vancomycin exposures did not confer a lower TF risk but were associated with more AKI. The findings suggest that vancomycin dosing should be guided by the AUC and day 2 AUCs should be \u2264515. As few patients had day 2 AUCs &amp;lt;400, further study is needed to define the lower bound of the therapeutic range.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz460","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T15:11:35Z","timestamp":1559315495000},"page":"1536-1545","source":"Crossref","is-referenced-by-count":142,"title":["The Emperor\u2019s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)"],"prefix":"10.1093","volume":"70","author":[{"suffix":"Jr.","given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Rosenkranz","sequence":"first","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Finnemeyer","sequence":"first","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Evans","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Biostatistics Center, George Washington University, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sims","sequence":"first","affiliation":[{"name":"William Beaumont Hospital, Royal Oak"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J","family":"Zervos","sequence":"first","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Buddy","family":"Creech","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratish C","family":"Patel","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keefer","sequence":"first","affiliation":[{"name":"University of Rochester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Riska","sequence":"first","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda P","family":"Silveira","sequence":"first","affiliation":[{"name":"University of Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Scheetz","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, and Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove"},{"name":"Northwestern Memorial Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Wunderink","sequence":"first","affiliation":[{"name":"Northwestern Memorial Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schrank","sequence":"first","affiliation":[{"name":"Greenville Hospital System University Medical Center, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C","family":"Bleasdale","sequence":"first","affiliation":[{"name":"University of Illinois Hospital and Health Sciences System, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Schultz","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Barron","sequence":"first","affiliation":[{"name":"University of Colorado Denver, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Stapleton","sequence":"first","affiliation":[{"name":"University of Washington Medical Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannah","family":"Wray","sequence":"first","affiliation":[{"name":"Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Chambers","sequence":"first","affiliation":[{"name":"San Francisco General Hospital, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Vance G","family":"Fowler","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L","family":"Holland","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"2020041000553604900_CIT0001","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"2020041000553604900_CIT0002","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/phar.1382","article-title":"Vancomycin: over 50 years later and still a work in progress","volume":"33","author":"Rybak","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2020041000553604900_CIT0003","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","author":"Rybak","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2020041000553604900_CIT0004","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/phar.1327","article-title":"Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals","volume":"33","author":"Davis","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2020041000553604900_CIT0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041000553604900_CIT0006","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041000553604900_CIT0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020041000553604900_CIT0008","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2020041000553604900_CIT0010","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041000553604900_CIT0011","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program\u2019s retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"2020041000553604900_CIT0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041000553604900_CIT0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2020041000553604900_CIT0014","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0015","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"2020041000553604900_CIT0016","volume-title":"Performance standards for antimicrobial disk susceptibility tests; approved standards","author":"Clinical and Laboratory Standards Institute","year":"2006","edition":"9th"},{"key":"2020041000553604900_CIT0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/JCM.01508-06","article-title":"A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides","volume":"45","author":"Wootton","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2020041000553604900_CIT0018","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D\u2019Argenio","year":"2009"},{"key":"2020041000553604900_CIT0019","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/529190","article-title":"Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia","volume":"46","author":"Jenkins","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0020","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2020041000553604900_CIT0021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0022","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"2020041000553604900_CIT0023","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0270-0255(86)90088-6","article-title":"A new approach to causal inference in mortality studies with a sustained exposure period\u2014application to control of the healthy worker survivor effect","volume":"7","author":"Robins","year":"1986","journal-title":"Math Model"},{"key":"2020041000553604900_CIT0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"2020041000553604900_CIT0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041000553604900_CIT0026","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020041000553604900_CIT0027","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0028","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020041000553604900_CIT0029","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1128\/JCM.00448-13","article-title":"Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods","volume":"51","author":"Rybak","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020041000553604900_CIT0030","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1128\/JCM.02215-10","article-title":"Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus","volume":"49","author":"Kruzel","year":"2011","journal-title":"J Clin Microbiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz460\/28757414\/ciz460.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/8\/1536\/33031750\/ciz460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/8\/1536\/33031750\/ciz460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T21:23:03Z","timestamp":1663536183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/8\/1536\/5510260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,6,3]]},"published-print":{"date-parts":[[2020,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz460","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735898503.793587615","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,15]]},"published":{"date-parts":[[2019,6,3]]}}}